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Table 1
Cytokine Levels and Clinical Outcome
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(Boyiadzis et al; BBMT, 2008) and cytokine levels were asso-
ciated with acute GVHD (IL-7) or pattern of immune recon-
stitution (IL-15). However, it is not knownwhether recipients
of lower-intensity conditioning or sirolimus-based GVHD
prophylaxis have variable levels of these cytokines or
whether such potential cytokine variability is associated
with clinical outcome. To begin to address this, wemeasured
multiple cytokine levels (MesoScale multiplex assay; current
analysis restricted to IL-7 and IL-15 levels at day 0 of trans-
plant) in recipients of low-intensity conditioning (Flu/Cy;
total Cy dose, 1200 mg/m2; see Table 1). Patients received
GVHD prophylaxis consisting of cyclosporine plus short-
course sirolimus (d2 through d14 post-SCT) at either
standard-dose (n¼46; “SD Cohort”) or high-dose (n¼20; “HD
Cohort”) (target trough level: 5-10 or 20-30 ng/ml,
respectively). All patients received pre-emptive DLI consist-
ing of rapamycin-resistant T cells (Fowler et al; Blood, 2013);
however, in the current study, T cell manufacturing was
reduced from 12 days to 6 days. Clinical outcomes (Table 1)
were similar in SD and HD Cohorts, including: donor T cell
and myeloid cell chimerism pre-DLI (d14 post-SCT) and
post-DLI (d28 post-SCT), and incidence of classical acute
GVHD. Remarkably, a wide range of IL-7 and IL-15 values
were detected at day 0 of SCT in both SD and HD Cohorts(no difference between cohorts). In the SD Cohort,
there was no association of IL-7 or IL-15 values with donor T
cell chimerism, myeloid cell chimerism, or acute GVHD.
However, in the HD Cohort, IL-7 values were associated with
donor T cell chimerism and GVHD; and, IL-15 values were
associated with donor T cell chimerism, myeloid cell
chimerism, as well as GVHD. In conclusion, these data indi-
cate that: (1) IL-7 and IL-15 values differ widely amongst
recipients of low-intensity conditioning; and (2) IL-7 and IL-
15 values were potentially associated with allo-engraftment
and GVHD in the setting of high-dose sirolimus but not
standard-dose sirolimus. This latter result provides a new
insight into the pharmacodynamics of mTOR blockade post-
transplant, and suggests that a more complete block of
cytokine receptor signaling in vivo can unmask relationships
between cytokine biology and post-transplant outcome.379
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Early cytomegalovirus (CMV) re-activation after allogeneic
hematopoetic stem cell transplantation (allo-HCT) for AML
has been correlated with enhanced graft versus leukemia
(GvL) effect, thus implying an immunogenetic cross-talk
between donor-derived cytotoxic response against both CMV
and leukemia. Data on this are conﬂicting and correlation
could not be conﬁrmed for special group populations. In this
study we explore whether CMV re-activation favors the
outcome in a group of 49 AML patients consecutively allo-
transplanted between 2008-2012. Forty-nine patients (29
male, 20 female), aged 14-63 years (median 42) underwent
allo-HCT with myelo-ablative (42/49) or reduced-intensity
conditioning (7/49), receiving graft from an HLA-identical
sibling (25/49), matched volunteer (23/49) or haplo-identical
(1) donor. Most patients were transplanted in complete
remission (CR), 22/49 in CR1 and 11/49 in CR2 and 16/49
patients had refractory disease. Monitoring of CMV viral load
was performed weekly for 3 months with real-time PCR or
more if patients were treated for GvHD. Upon clinical suspi-
cion, other samples were tested. Overall, 19/49 patients (39%)
presented with CMV reactivation {viremia (>¼1000 copies/
ml) in 16/49, gastritis in 2/49, cystitis in 1) at a median of 46
days post-transplant (13-402). Leukemia relapse occurred in
7/19 patients with CMV at a median of 189 days (2-512),
versus 7/30 CMV-free patients (37% vs 23%, p¼ns). Disease
free survival (DFS) was 591 days for CMV patients (95% CI:
417-939) and 609 for CMV-free (95% CI: 474-871, p¼ns).
Overall survival (OS) was 746 (95% CI:472-963) and 625 (95%
CI:504-899) days, respectively, p¼ns. Only acute and chronic
GvHDwere correlated with longer DFS and OS. Sixteen out of
19 CMV (84%) patients presented with increasing/full donor
chimerism 30 days after reactivation, due to expansion of
donor cytotoxic lymphocytes; however, this did not protect
from imminent relapse. No particular clinical correlations
could be found even for 14/19 patientswith early (<100 days)
CMV reactivation (RR: 28% vs 28% for all other patients, DFS:
714 vs 503 days, OS: 746 vs 625 days, p¼ns for all compari-
sons). In conclusion, CMV reactivation in AML transplanted
patients is not related to graft allo-reactivity. Late relapses in
this cohort of AML patients, transplanted often in remission,
are not inﬂuenced by immunogenetic dynamics at the ﬁrst
semester, when CMV occurs. Regardless CMV re-activation,
OS was comparable in all patients, providing evidence on a
successful pre-emptive treatment of CMV. Larger prospective
studies are strongly warranted in order to explore possible
immunogenetic interactions.380
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Introduction: Bacteremia occurs frequently in the
neutropenic period of earlyallogeneic stemcell transplantation
(SCT). Effective strategies have been developed for
the rapid diagnosis and management of bacteremia inimmunocompromised SCT recipients. We analyzed the inci-
dence of bacteremia during TBI-based myeloablative SCT to
determine the impact on morbidity and mortality in a recent
cohort of patients.
Methods: We studied outcomes in a cohort of 105 consec-
utive ex vivo T cell depleted (TCD) allogeneic transplants
from 6/6 HLA-matched sibling donors between 2006e2014.
Prophylactic antibiotics were not administered. Blood stream
infection (BSI) was deﬁned as the isolation of bacteria from
any blood culture in a four-week window (between days -8
to +21) during the initial hospitalization. All patients had
hematologic malignancies and received myeloablative
conditioning with ﬂudarabine (125 mg/m2), age-adapted
fractionated TBI and cyclophosphamide (120 mg/kg). Frac-
tionated TBI was delivered at a total dose of 1200cGy (with
lung shielding to 600cGy for subjects age <55 years) or 400-
600cGy for subjects age 55 years. All subjects were
managed as inpatients with prompt empiric broad spectrum
antibiotics at the ﬁrst onset of a neutropenic fever.
Results: Successful neutrophil recovery occurred in all sub-
jects and the median time to ANC 500/uL was 13 days. Out
of 105 subjects, 71 (67.5%) had a BSI and 63% occurred be-
tween days 0 to +7. Bacterial species isolated from the blood
were classiﬁed according to their probable site of origin as
oral/cutaneous gram-positive organisms (32%), other sites
(mostly gram-negative) (34%), or mixed (34%). Organisms
classiﬁed as oral/cutaneous were most frequently Strepto-
coccus (44%) or Staphylococcus (43%) species while E. coli
(36%), Klebsiella (27%) and Enterococci (18%) were the most
common isolates classiﬁed as from other sites. One patient
(<1%) succumbed to neutropenic polymicrobial septic shock
on day+7. The occurrence of BSI was not predicted by pre-
transplant factors such as age, gender, type of underlying
malignancy or TBI dose. Even in the subgroup with oral/
cutaneous organisms, BSI was unrelated to the intensity of
oral mucositis (p¼0.16). There was no association between
BSI and early outcomes such as the duration of initial hos-
pitalization (p¼0.70), requirement for total parenteral
nutrition (TPN) (p¼0.38), duration of TPN(p¼0.49) or transfer
to the intensive care unit (p¼0.34). In addition, BSI exerted no
statistically signiﬁcant impact on delayed outcomes such as
non-relapse mortality (p¼0.6) or overall survival (p¼0.5).
Conclusion: Early BSI is common during TBI-based condi-
tioning, with a peak incidence between days 0 and 7, and is
not associatedwith conditioning intensity or presence of oral
mucositis. With optimal management, BSI does not impact
short or long-term outcomes in allogeneic SCT recipients.381
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Allogeneic hematopoetic cell transplantation (allo-HCT) is
currently the only curative treatment option for non-M3
